Objective: To explore the effect of thymalfasin on coagulation index, immune function, PCT and sTREM-1 levels in patients with community acquired pneumonia. Methods: 160 patients with community acquired pneumonia admi...Objective: To explore the effect of thymalfasin on coagulation index, immune function, PCT and sTREM-1 levels in patients with community acquired pneumonia. Methods: 160 patients with community acquired pneumonia admitted in our hospital from June 2016-June 2017 were divided into the control group and the observation group according to the random number table method, each 80 cases. The control group was given conventional treatment, while the observation group was given thymalfasin on the basis of conventional treatment. The levels of D-D, FBG, complement C3, C4, T lymphocyte subsets, PCT and sTREM-1 were detected before and after treatment. Results: Before treatment, there was no statistical difference between the serum levels of D-D, FBG, C3, C4, CD3+,CD4+,CD8+,CD4+/CD8+, PCT and sTREM-1 in the two groups of patients, and P>0.05. After treatment, the levels of CD3+, CD4+and CD4+/CD8+ in the control group and the observation group were significantly increased, and the levels of D-D, FBG, CD8+, PCT and sTREM-1 were significantly decreased, and the level of CD3+, CD4+ and CD4+/CD8+ in the observation group was significantly higher than that of the control group after treatment, and the D-D, FBG, CD8+, PCT and sTREM-1 levels were significantly lower than those in the control group, the difference was statistically significant, P<0.05. Conclusion: Thymalfasin has a certain clinical effect in the treatment of patients with community acquired pneumonia. It can significantly improve the blood coagulation function, enhance the immune ability and alleviate the inflammatory state.展开更多
文摘Objective: To explore the effect of thymalfasin on coagulation index, immune function, PCT and sTREM-1 levels in patients with community acquired pneumonia. Methods: 160 patients with community acquired pneumonia admitted in our hospital from June 2016-June 2017 were divided into the control group and the observation group according to the random number table method, each 80 cases. The control group was given conventional treatment, while the observation group was given thymalfasin on the basis of conventional treatment. The levels of D-D, FBG, complement C3, C4, T lymphocyte subsets, PCT and sTREM-1 were detected before and after treatment. Results: Before treatment, there was no statistical difference between the serum levels of D-D, FBG, C3, C4, CD3+,CD4+,CD8+,CD4+/CD8+, PCT and sTREM-1 in the two groups of patients, and P>0.05. After treatment, the levels of CD3+, CD4+and CD4+/CD8+ in the control group and the observation group were significantly increased, and the levels of D-D, FBG, CD8+, PCT and sTREM-1 were significantly decreased, and the level of CD3+, CD4+ and CD4+/CD8+ in the observation group was significantly higher than that of the control group after treatment, and the D-D, FBG, CD8+, PCT and sTREM-1 levels were significantly lower than those in the control group, the difference was statistically significant, P<0.05. Conclusion: Thymalfasin has a certain clinical effect in the treatment of patients with community acquired pneumonia. It can significantly improve the blood coagulation function, enhance the immune ability and alleviate the inflammatory state.
